ES2287343T3 - Uso de una dosis especifica de fondaparinux sodico para el tratammiento de sca. - Google Patents
Uso de una dosis especifica de fondaparinux sodico para el tratammiento de sca. Download PDFInfo
- Publication number
- ES2287343T3 ES2287343T3 ES02787601T ES02787601T ES2287343T3 ES 2287343 T3 ES2287343 T3 ES 2287343T3 ES 02787601 T ES02787601 T ES 02787601T ES 02787601 T ES02787601 T ES 02787601T ES 2287343 T3 ES2287343 T3 ES 2287343T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- dose
- sulfo
- fondaparinux
- sulfoamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 229960001318 fondaparinux Drugs 0.000 title description 3
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 title description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 201000011244 Acrocallosal syndrome Diseases 0.000 claims description 14
- 208000019905 acrocephalosyndactyly Diseases 0.000 claims description 14
- 206010051895 acute chest syndrome Diseases 0.000 claims description 14
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 5
- -1 2-deoxy-2-sulfoamino-6-O-sulfo-alpha-D-glucopyranosyl Chemical group 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 3
- QRDZSRWEULKVNW-UHFFFAOYSA-N 6-hydroxy-2-oxo-1h-quinoline-4-carboxylic acid Chemical compound C1=C(O)C=C2C(C(=O)O)=CC(=O)NC2=C1 QRDZSRWEULKVNW-UHFFFAOYSA-N 0.000 abstract 1
- 125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 abstract 1
- XEKSTYNIJLDDAZ-JASSWCPGSA-D decasodium;(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4-hydroxy-6-[(2r,3s,4r,5r,6s)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sul Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C([O-])=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C([O-])=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-D 0.000 description 17
- 208000032843 Hemorrhage Diseases 0.000 description 16
- 229960003661 fondaparinux sodium Drugs 0.000 description 16
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 15
- 230000034994 death Effects 0.000 description 10
- 231100000517 death Toxicity 0.000 description 10
- 229960000610 enoxaparin Drugs 0.000 description 9
- 208000034158 bleeding Diseases 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 206010000891 acute myocardial infarction Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 206010051055 Deep vein thrombosis Diseases 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 206010047249 Venous thrombosis Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940127215 low-molecular weight heparin Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 206010002388 Angina unstable Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 108010029144 Factor IIa Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010056457 Intra-abdominal haematoma Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01204323 | 2001-11-13 | ||
| EP01204323 | 2001-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2287343T3 true ES2287343T3 (es) | 2007-12-16 |
Family
ID=8181220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02787601T Expired - Lifetime ES2287343T3 (es) | 2001-11-13 | 2002-11-07 | Uso de una dosis especifica de fondaparinux sodico para el tratammiento de sca. |
Country Status (36)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090075910A1 (en) * | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched fondaparinux |
| JP6869894B2 (ja) * | 2015-03-20 | 2021-05-12 | オーフス ウニベルシテット | リポタンパク質代謝障害の治療のためのｐｃｓｋ９阻害剤 |
| US10688249B2 (en) * | 2015-06-11 | 2020-06-23 | Virchow Biotech Pvt. Ltd. | Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same |
| CN107595769A (zh) * | 2017-10-23 | 2018-01-19 | 上海博悦生物科技有限公司 | 一种磺达肝癸钠注射液组合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2662442A1 (fr) * | 1990-05-23 | 1991-11-29 | Midy Spa | Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant. |
| CA2199642C (en) * | 1997-03-10 | 2001-05-08 | Roger Cariou | Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin |
| FR2764511B1 (fr) * | 1997-06-13 | 2000-09-08 | Sanofi Sa | Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire |
| EP1551852A4 (en) * | 2002-04-25 | 2007-03-21 | Momenta Pharmaceuticals Inc | METHOD AND PRODUCTS FOR MUCOSAL DELIVERY |
-
2002
- 2002-07-11 UA UA2004032373A patent/UA80399C2/uk unknown
- 2002-11-07 US US10/492,102 patent/US20040248848A1/en not_active Abandoned
- 2002-11-07 CA CA002465776A patent/CA2465776A1/en not_active Abandoned
- 2002-11-07 IL IL16111402A patent/IL161114A0/xx unknown
- 2002-11-07 JP JP2003543609A patent/JP4523276B2/ja not_active Expired - Fee Related
- 2002-11-07 DE DE60220084T patent/DE60220084T2/de not_active Expired - Lifetime
- 2002-11-07 RS YUP-267/04A patent/RS50906B/sr unknown
- 2002-11-07 SI SI200230578T patent/SI1446131T1/sl unknown
- 2002-11-07 WO PCT/EP2002/012482 patent/WO2003041722A1/en not_active Ceased
- 2002-11-07 BR BR0212915-9A patent/BR0212915A/pt not_active Application Discontinuation
- 2002-11-07 KR KR1020047004779A patent/KR20050044318A/ko not_active Ceased
- 2002-11-07 EP EP02787601A patent/EP1446131B1/en not_active Expired - Lifetime
- 2002-11-07 AT AT02787601T patent/ATE361753T1/de active
- 2002-11-07 HU HU0401462A patent/HU228959B1/hu unknown
- 2002-11-07 ES ES02787601T patent/ES2287343T3/es not_active Expired - Lifetime
- 2002-11-07 PT PT02787601T patent/PT1446131E/pt unknown
- 2002-11-07 ME MEP-11/08A patent/MEP1108A/xx unknown
- 2002-11-07 PL PL369027A patent/PL206008B1/pl unknown
- 2002-11-07 GE GE5516A patent/GEP20074097B/en unknown
- 2002-11-07 ME MEP-2008-11A patent/ME00229B/me unknown
- 2002-11-07 AP APAP/P/2004/003014A patent/AP1820A/en active
- 2002-11-07 AU AU2002351915A patent/AU2002351915B2/en not_active Expired
- 2002-11-07 MX MXPA04003045A patent/MXPA04003045A/es active IP Right Grant
- 2002-11-07 HR HR20040303A patent/HRP20040303B1/xx not_active IP Right Cessation
- 2002-11-07 CN CNA028192567A patent/CN1602197A/zh active Pending
- 2002-11-07 EA EA200400382A patent/EA007325B1/ru unknown
- 2002-11-07 DK DK02787601T patent/DK1446131T3/da active
- 2002-11-07 PE PE2002001086A patent/PE20030740A1/es not_active Application Discontinuation
- 2002-11-07 NZ NZ552129A patent/NZ552129A/en not_active IP Right Cessation
- 2002-11-11 AR ARP020104308A patent/AR037291A1/es unknown
-
2004
- 2004-03-25 IL IL161114A patent/IL161114A/en active IP Right Grant
- 2004-03-29 ZA ZA2004/02464A patent/ZA200402464B/en unknown
- 2004-03-29 IS IS7199A patent/IS2484B/is unknown
- 2004-03-30 NO NO20041320A patent/NO20041320L/no not_active Application Discontinuation
- 2004-03-31 EC EC2004005041A patent/ECSP045041A/es unknown
- 2004-03-31 CO CO04030711A patent/CO5580790A2/es not_active Application Discontinuation
- 2004-03-31 MA MA27602A patent/MA27071A1/fr unknown
-
2007
- 2007-07-30 CY CY20071101000T patent/CY1106765T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rosen et al. | High‐dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma | |
| Blumberg et al. | Clinical trials of WR-2721 with radiation therapy | |
| Rankin et al. | Adenosine or adenosine triphosphate forsupraventricular tachycardias? Comparative double-blind randomized study in patients with spontaneous or inducible arrhythmias | |
| Weaver et al. | New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction | |
| US9295687B1 (en) | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | |
| ES2287343T3 (es) | Uso de una dosis especifica de fondaparinux sodico para el tratammiento de sca. | |
| ES2249707T3 (es) | Tratameinto de combinacion para infarto de miocardio agudo. | |
| JP2005509007A6 (ja) | Ａｃｓの治療のためのフォンダパリヌックスナトリウムの特定投与量の使用 | |
| AU2002351915A1 (en) | Uso of specific dose of fondaparinux sodium for the treatment of ACS | |
| ES2904256T3 (es) | Métodos para tratar, reducir la incidencia de y/o prevenir eventos isquémicos | |
| US20200206252A1 (en) | Use of ribose in first response to acute myocardial infarction | |
| ES2262971T3 (es) | Idraparinux (sanorg 34006) para el tratamiento y profilaxis secundaria de sucesos tromboembolicos venosos en pacientes con trombosis venosa intensa. | |
| HK1070561B (en) | Use of specific dose of fondaparinux sodium for the treatment of acs | |
| JPS6354690B2 (enExample) | ||
| KR20150047515A (ko) | 관상동맥 우회로 이식술이 예정된 환자의 st 비상승 급성 관상동맥 증후군 치료에 사용되는 오타믹사반 | |
| Jimenez | Idiopathic migratory thrombophlebitis: Report of 4 cases | |
| Catalano et al. | Bleomycin | |
| MXPA05003625A (es) | Terapia de combinacion con gencitabina y zd6126. |